Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol

Peer Review reports

Original Submission
30 Jan 2024	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
30 Apr 2024	Author responded	Author comments - A.A.M. van der Veldt
Resubmission - Version 3
30 Apr 2024	Submitted	Manuscript version 3
Publishing
3 May 2024	Editorially accepted
23 May 2024	Article published	10.1186/s12885-024-12336-0

Back to article page